Cargando…

Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus on Patient Selection and Clinical Perspectives

Dapagliflozin is a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor that was recently approved in the USA and the EU for the treatment of adults with chronic kidney disease (CKD) with or without diabetes mellitus (DM). The DAPA-CKD trial showed a 39% decline in the risk of worsening kidney...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nashar, Khaled, Khalil, Patricia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636858/ https://www.ncbi.nlm.nih.gov/pubmed/36345396 http://dx.doi.org/10.2147/IJNRD.S234282

Ejemplares similares

Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives
por: Lim, Sian Yik, et al.
Publicado: (2022)

Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
por: Vart, Priya, et al.
Publicado: (2022)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
por: Yu, Huan, et al.
Publicado: (2017)

Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
por: Escobar, Carlos, et al.
Publicado: (2023)

The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD
por: Iwata, Yukimasa, et al.
Publicado: (2023)

Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
por: Wheeler, David C, et al.
Publicado: (2021)

Clinical studies of dapagliflozin in pediatric patients: a rapid review
por: Grube, Paige M., et al.
Publicado: (2022)

Relationship between chronic kidney disease and metabolic syndrome: current perspectives
por: Nashar, Khaled, et al.
Publicado: (2014)

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
por: Wheeler, David C, et al.
Publicado: (2020)

Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial
por: Marx, Nikolaus, et al.
Publicado: (2021)

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
por: Beernink, Jelle M., et al.
Publicado: (2023)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
por: Chertow, Glenn M., et al.
Publicado: (2023)

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou, Ioanna, et al.
Publicado: (2019)

Clinical Significance of FGF-23 in Patients with CKD
por: Russo, Domenico, et al.
Publicado: (2011)

Emerging Role of Clinical Genetics in CKD
por: Devarajan, Prasad, et al.
Publicado: (2022)

An exploration of the experience of dapagliflozin in clinical practice
por: Anitha, Anuba Paulvarnan, et al.
Publicado: (2022)

Potassium Metabolism and Management in Patients with CKD
por: Yamada, Shinsuke, et al.
Publicado: (2021)

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
por: Persson, Frederik, et al.
Publicado: (2021)

The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy
por: Huang, Ying, et al.
Publicado: (2022)

Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin
por: Salvo, Marissa C, et al.
Publicado: (2014)

Clinical significance of parathyroid intervention on CKD-MBD management
por: Ogata, Hiroaki, et al.
Publicado: (2008)

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives
por: Iaxx, Romain, et al.
Publicado: (2022)

The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
por: Provenzano, Michele, et al.
Publicado: (2021)

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
por: Gupta, Manasvi, et al.
Publicado: (2021)

Clinical Evaluation of Avelumab in the Treatment of Advanced Urothelial Carcinoma: Focus on Patient Selection and Outcomes
por: Ten Eyck, Jennifer E, et al.
Publicado: (2022)

Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials
por: Sprangers, Ben, et al.
Publicado: (2022)

Evaluation and management of hypernatremia in adults: clinical perspectives
por: Yun, Giae, et al.
Publicado: (2023)

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
por: Heerspink, Hiddo J L, et al.
Publicado: (2021)

Microbiome in Chronic Kidney Disease (CKD): An Omics Perspective
por: Lohia, Sonnal, et al.
Publicado: (2022)

Symptom Management in Patients with Stage 5 CKD Opting for Conservative Management
por: Johnston, Sheila
Publicado: (2016)

Healthcare professionals’ perspectives on facilitators of and barriers to CKD management in primary care: a qualitative study in Singapore clinics
por: Ramakrishnan, Chandrika, et al.
Publicado: (2022)

Native Hypovitaminosis D in CKD Patients: From Experimental Evidence to Clinical Practice
por: Alfieri, Carlo, et al.
Publicado: (2019)

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
por: Waijer, Simke W., et al.
Publicado: (2022)

Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
por: De Matteis, Eleonora, et al.
Publicado: (2022)

Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives
por: Camiña-Conforto, Gemma, et al.
Publicado: (2023)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

Management and outcomes of heart failure patients with CKD: experience from an inter‐disciplinary clinic
por: Nguyen, Mai, et al.
Publicado: (2020)

Focus on the Possible Role of Dietary Sodium, Potassium, Phosphate, Magnesium, and Calcium on CKD Progression
por: Mazzaferro, Sandro, et al.
Publicado: (2021)

Perceived and Objective Kidney Disease Knowledge in Patients With Advanced CKD Followed in a Multidisciplinary CKD Clinic
por: Molnar, Amber O., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fdojt4u7meavvan6b59on0d6ka